Diabetes is a metabolic disorder characterized by hyperglycemia. When not properly controlled, complications
include neuropathy, coronary artery disease, and renal failure. Several drugs are approved for diabetes treatment; however
their use is associated with side effects and lack of efficacy in attenuating the development of long-term complications.
This work describes the virtual screening and synthesis of a novel series of sulfonylhydrazone derivatives designed as
peroxisome proliferator-activated receptor gamma (PPARγ) agonists and investigation of the analogs for hypoglycemic
activity in a murine model of diabetes. Docking studies identified LASSBio-331 (5) as having theoretical affinity for
PPARγ similar to the prototype (S)-rosiglitazone. Several structural modifications were proposed for the structure of
LASSBio-331, resulting in the synthesis of five novel compounds, which showed experimental affinity for PPARγ.
Among these new compounds, LASSBio-1471 (15) had the best theoretical binding energy for PPARγ and was selected
for testing in STZ-induced diabetes. Four weeks after single intravenous injection of STZ (60 mg/kg), Wistar rats were
treated with vehicle (DMSO) or LASSBio-1471 (20 mg/kg, i.p.) for 7 days. The blood glucose levels of rats treated with
LASSBio-1471 were reduced from 548.4 ± 26.0 mg/dL before treatment to 259.6 ± 73.1 mg/dL (P < 0.05). Paw withdrawal
threshold was significantly reduced in diabetic rats and was restored from 21.9 ± 1.7 g to 36.7 ± 1.2 g after 7 days
of treatment with LASSBio-1471 (P < 0.05). Thus, the novel sulfonylhydrazone derivative is a PPARγ ligand that is effective
for treatment of diabetic neuropathy in STZ-injected rats.
Keywords: Diabetic neuropathy, virtual screening, sulfonylhydrazone, hypoglycemic activity, PPARγ, metabolic disorder, Diabetes mellitus (DM), coronary heart disease, hyperglycemia, antidiabetic agents, postural hypotension.
Rights & PermissionsPrintExport